We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$127B
1-Year Est. Return
46.06%
This Fund
S&P 500
This Quarter
Est. Return
+26.15%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+787.47%
AUM
$127B
AUM Growth
+$26.3B
(+26%)
Cap. Flow
+$9.28B
Cap. Flow
% of AUM
7.32%
Top 10 Holdings %
Top 10 Hldgs %
37.66%
Holding
3,898
New
771
Increased
1,083
Reduced
1,182
Closed
795
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$9.86B |
| 2 |
Costco
COST
|
+$907M |
| 3 |
AbbVie
ABBV
|
+$643M |
| 4 |
JPMorgan Chase
JPM
|
+$609M |
| 5 |
Bank of America
BAC
|
+$567M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.03B |
| 2 |
Mercado Libre
MELI
|
+$528M |
| 3 |
Broadcom
AVGO
|
+$514M |
| 4 |
SNDK
Sandisk
SNDK
|
+$507M |
| 5 |
Marvell Technology
MRVL
|
+$499M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 34.91% |
| 2 | Technology | 20.64% |
| 3 | Consumer Discretionary | 9.1% |
| 4 | Healthcare | 8.21% |
| 5 | Financials | 7.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Immunovant
IMVT
$8.17B
| $5.49M | ﹤0.01% |
142,488
-22,812
| -14% | -$695K |
|
1302
Capital Group International Focus Equity ETF
CGXU
$6.94B
| $5.48M | ﹤0.01% |
+158,399
| New | +$5.26M |
|
1303
First Busey Corp
BUSE
$2.51B
| $5.48M | ﹤0.01% |
185,782
+95,466
| +106% | +$2.59M |
|
1304
Oculis Holding
OCS
$675M
| $5.48M | ﹤0.01% |
+394,880
| New | +$8.96M |
|
1305
Northern Trust
NTRS
$33.8B
| $5.47M | ﹤0.01% |
31,461
+26,598
| +547% | +$4.38M |
|
1306
AngioDynamics
ANGO
$629M
| $5.47M | ﹤0.01% |
420,378
-65,126
| -13% | -$741K |
|
1307
Tango Therapeutics
TNGX
$3.83B
| $5.47M | ﹤0.01% |
+174,909
| New | +$4.32M |
|
1308
SL Green Realty
SLG
$3.74B
| $5.46M | ﹤0.01% |
+105,446
| New | +$4.71M |
|
1309
iShares Emerging Markets Dividend ETF
DVYE
$1.29B
| $5.44M | ﹤0.01% |
168,875
-12,002
| -7% | -$413K |
|
1310
Unity
U
$18.8B
| $5.43M | ﹤0.01% |
190,002
-1,255,757
| -87% | -$33.4M |
|
1311
Valens Semiconductor
VLN
$183M
| $5.43M | ﹤0.01% |
2,401,143
+572,762
| +31% | +$1.28M |
|
1312
Groupon
GRPN
$771M
| $5.42M | ﹤0.01% |
+225,216
| New | +$3.72M |
|
1313
TransDigm Group
TDG
$63.3B
| $5.41M | ﹤0.01% |
4,060
-48,131
| -92% | -$59.1M |
|
|
AVEX
1314
AEVEX Corp
AVEX
$966M
| $5.38M | ﹤0.01% |
+257,447
| New | +$6.69M |
|
|
DPC
1315
DPC Holdings PLC
DPC
$6.39B
| $5.37M | ﹤0.01% |
+109,392
| New | +$5.33M |
|
|
BLLN
1316
BillionToOne Inc
BLLN
$4.67B
| $5.36M | ﹤0.01% |
+44,662
| New | +$4.08M |
|
1317
Towne Bank
TOWN
$3.43B
| $5.36M | ﹤0.01% |
147,798
-307,785
| -68% | -$10.7M |
|
1318
CALL
Palantir
PLTR
$409B
| $5.34M | ﹤0.01% |
45,800
-2,200
| -5% | -$300K |
|
|
NPKI
1319
NPK International
NPKI
$1.15B
| $5.34M | ﹤0.01% |
335,734
+281,617
| +520% | +$4.25M |
|
1320
Ultragenyx Pharmaceutical
RARE
$1.47B
| $5.34M | ﹤0.01% |
159,889
+2,363
| +2% | +$58.7K |
|
1321
Flex
FLEX
$42.2B
| $5.34M | ﹤0.01% |
+32,921
| New | +$3.99M |
|
1322
PagerDuty
PD
$1.05B
| $5.32M | ﹤0.01% |
551,665
+115,015
| +26% | +$871K |
|
|
OCTV
1323
Octave Intelligence
OCTV
$4.94B
| $5.31M | ﹤0.01% |
+325,489
| New | +$5.98M |
|
1324
UWM Holdings
UWMC
$2.23B
| $5.3M | ﹤0.01% |
2,316,186
+2,106,530
| +1,005% | +$6.55M |
|
1325
Treace Medical Concepts
TMCI
$301M
| $5.29M | ﹤0.01% |
1,328,592
+1,063,659
| +401% | +$2.92M |
|
Similar funds
Marshall Wace's Q2 2026 Portfolio in Review
As of Q2 2026, Marshall Wace held 3,898 positions worth $127B, up 26% from $100B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Marshall Wace deployed $9.28B of net new capital in Q2 2026, opening 771 new positions and adding to 1,083 existing holdings. Its largest new stake was LPL Financial: 975,627 shares worth $275M.
By sector, the portfolio is most concentrated in Miscellaneous at 35% of assets, up from 30% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $1.03B trimmed.
- Marshall Wace's largest Q2 2026 buy was LPL Financial: 975,627 shares worth $275M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.86B increase.
- Marshall Wace's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.03B.
- Marshall Wace fully exited Merck in Q2 2026, selling an estimated $325M.
- Marshall Wace's ten largest holdings make up 38% of its $127B portfolio in Q2 2026.
- Marshall Wace opened 771 new positions and closed 795 in Q2 2026.
- Marshall Wace's portfolio value rose 26% quarter-over-quarter to $127B.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.